Greetings, and welcome to the Pulse Biosciences' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...

Hims & Hers (HIMS) is down -14.6%, or -$3.25 to $19.00. Published first on TheFly – the ultimate source for real-time, ...

Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...

Shares of Hims & Hers (NYSE:HIMS) fell 15% Wednesday following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no ...

The FDA on Wednesday updated its drug shortage database to say that all dosages and versions of Novo Nordisk's Wegovy and Ozempic are ...

With the cost of GLP-1s rising for employers, so-called compounded weight-loss drugs have emerged as a more cost-conscious ...

Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...